Stock 603351 NANJING WELL PHARMACEUTICAL GROUP CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Nanjing Well Pharmaceutical Group Co.,Ltd.

Equities

603351

CNE100003JD4

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 30/04/2024 am IST 		5-day change 1st Jan Change
24.68 CNY +2.41% Intraday chart for Nanjing Well Pharmaceutical Group Co.,Ltd. +3.87% -6.41%
25/04 Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. completed the acquisition of13% stake in Nanjing Xingwei Biotechnology Co., Ltd. from Wu Renrong, Gao Zhengsong, Chen Xinguo, Tang Qunsong, Shen Jiusi, Wu Rongwen, Hong Shilin, Zou Jianguo, Wang Fuqiu and Zhou Chong.
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. signed an agreement to acquire 13% stake in Nanjing Xingwei Biotechnology Co., Ltd. from Wu Renrong, Gao Zhengsong, Chen Xinguo, Tang Qunsong, Shen Jiusi, Wu Rongwen, Hong Shilin, Zou Jianguo, Wang Fuqiu and Zhou Chong for CNY0.
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Certain A Shares of Nanjing Well Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 30-JAN-2022.
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020
CI
Nanjing Well Pharmaceutical Group Co.,Ltd.(XSSC:603351) dropped from S&P Global BMI Index
CI
Nanjing Well Pharmaceutical Co., Ltd. Announces Cash Dividend for the Year 2019, Payable on May 27, 2020
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 603351 Stock
  4. News Nanjing Well Pharmaceutical Group Co.,Ltd.